Ken Griffin Orchard Therapeutics PLC Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.36 - $0.49 $1,430 - $1,946	3,973 Added 0.17%	2,294,315 $848,000
Q3 2022 Nov 14, 2022	BUY	$0.45 - $0.69 $1.02 Million - $1.57 Million	2,268,933 Added 10598.03%	2,290,342 $1.15 Million
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.78 $54,557 - $101,320	-129,898 Reduced 85.85%	21,409 $13,000
Q1 2022 May 16, 2022	SELL	$0.7 - $1.51 $26,692 - $57,579	-38,132 Reduced 20.13%	151,307 $108,000
Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.23 $6,758 - $12,991	-5,826 Reduced 2.98%	189,439 $250,000
Q3 2021 Nov 15, 2021	SELL	$2.24 - $4.29 $157,346 - $301,346	-70,244 Reduced 26.46%	195,265 $449,000
Q2 2021 Aug 16, 2021	SELL	$4.39 - $7.23 $242,209 - $398,900	-55,173 Reduced 17.2%	265,509 $1.17 Million
Q1 2021 May 17, 2021	BUY	$4.39 - $9.08 $1.21 Million - $2.49 Million	274,652 Added 596.68%	320,682 $2.33 Million
Q4 2020 Feb 16, 2021	BUY	$3.86 - $5.07 $102,486 - $134,613	26,551 Added 136.31%	46,030 $199,000
Q3 2020 Nov 16, 2020	SELL	$4.11 - $6.45 $5.48 Million - $8.6 Million	-1,333,635 Reduced 98.56%	19,479 $80,000
Q2 2020 Aug 14, 2020	BUY	$5.75 - $11.99 $2.81 Million - $5.85 Million	488,069 Added 56.42%	1,353,114 $8.12 Million
Q1 2020 May 15, 2020	BUY	$5.65 - $15.71 $2.03 Million - $5.64 Million	359,168 Added 71.0%	865,045 $6.51 Million
Q4 2019 Feb 14, 2020	SELL	$10.15 - $15.58 $1.42 Million - $2.18 Million	-139,983 Reduced 21.67%	505,877 $6.96 Million
Q3 2019 Nov 14, 2019	BUY	$11.88 - $16.72 $7.67 Million - $10.8 Million	645,860 New	645,860 $7.67 Million

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.